邮箱：sunzxcn@hotmail.com
个人简介
孙震晓，博士，教授，博士生导师。中国环境诱变剂学会风险评价专业委员会常务委员。1997年beat365官方网站中药学专业博士毕业，2004年至今，beat365官方网站教授。承担过多项国家及省部级课题，发表学术论文120余篇，专著3部，获授权发明专利4项。
研究方向
中药抗肿瘤分子细胞药理学、中药分子细胞毒理学、人尿源性干细胞基础与应用研究。
主要成果
(1) Hu Yinghuan; Quan Zhengyang; Li Dengke; Wang Chenyu, Sun Zhenxiao*; Inhibition of CYP3A4 enhances aloe-emodin induced hepatocyte injury. Toxicology in Vitro, 2022, 79: 105276.
(2) Li Yiqun; Li Kaiming; Zhao Yan; Li Yong; Li Dengke; Shen Liangliang; Wang Qing; Yang Hsin-Sheng; Sun Zhenxiao*; Emodin-8-O-β-D-glucopyranoside, a natural hydroxyanthraquinone glycoside from plant, suppresses cancer cell proliferation via p21-CDKs-Rb axis, Toxicology and Applied Pharmacology, 2022, 438: 115909.
(3) Hu Yinghuan; Li Dengke; Quan Zhengyang; Wang Chengyu; Zhou Ming; Sun Zhenxiao*; Exploration of components and mechanisms of Polygoni Multiflori Radix-induced hepatotoxicity using siRNA -mediated CYP3A4 or UGT1A1 knockdown liver cells, Journal of Ethnopharmacology, 2021, 24(270):113845.
(4) Zhou Ming; Shen Liangliang; Qiao Yinggu; Sun Zhenxiao*; Inducing differentiation of human urine-derived stem cells into hepatocyte-like cells by coculturing with human hepatocyte L02 cells, Journal of Cellular Biochemistry, 2020,121: 566-573.
(5) Li Yong; Li Yiqun; Li Dengke; Li Kaiming; Quan Zhengyang; Wang Ziyi; Sun Zhenxiao*; Repositioning of hypoglycemic drug linagliptin for cancer treatment, Frontiers in Pharmacology, 2020, 11: 187.
(6) 孙震晓; 周明; 沈亮亮 ; 一种诱导人尿源性干细胞向肝细胞分化的方法, 2021-06-04, 中国, ZL 2019 1 0072291.8
(7) 孙震晓; 李勇; 李轶群 ; 利拉利汀的抗肿瘤活性及其新用途, 2021-06-04, 中国, ZL 2018 1 1403879.9
(8) 孙震晓; 李登科; 李宝赛; 王如峰 ; 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途, 2015-04-01, 中国, ZL 2013 1 0087383.6